NTx Bio Powers Baylor College of Medicine’s Manufacturing of a Personalized Cancer Vaccine in Diakonos Oncology’s Phase 1 Refractory Melanoma Trial

NTx Bio, a leader in next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used by researchers at Baylor College of Medicine to manufacture mRNA for a personalized dendritic cell vaccine (DCV) now in clinical use in an industry-sponsored Phase 1 trial for refractory melanoma, marking one of the first publicly disclosed clinical translations of NTx’s continuous-flow manufacturing platform.

BioSkryb Genomics Names William E. Evans, Pharm.D. as Chief Executive Officer

BioSkryb Genomics, a pioneer in single-cell and ultra-low-input multiomic solutions, today announced that William E. Evans, Pharm.D., has been appointed as Chief Executive Officer. Dr. Evans has served on BioSkryb’s Board of Directors and as Chair of its Scientific Advisory Board since 2019. He succeeds Suresh Pisharody, who has departed the company to pursue other opportunities.